Abveris Again Named as One of the Best Places to Work in 2022
Canton, MA—March 10, 2022—The Business...
Traditionally, display technologies (in vitro methods) are the major routes for VHH discovery. However, display technologies are not optimized for cell surface targets as cell-based screening could not be consistently incorporated into the panning process. This has led to significant attritions of on-cell binding hits coming out from the screening funnel.
Abveris has developed an optimized in vivo discovery workflow based on immunized camelids tailored for cell surface targets. Abveris leverages an industry-leading Beacon-based single B cell screening platform, enabling the rapid identification of on-cell binders with required activities and/or cross-reactivity in just 1 day.
Figure 1. The longer CDR3 of VHHs is advantageous for accessing epitopes
on cell surface targets that cannot be reached with conventional IgG molecules
Figure 2. VHHs are versatile building blocks that offer convenient
and scalable paths to the production of bispecifics and multispecifics
No royalty or milestone terms for discovery campaigns initiated in 2022